AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
_6ff029a61766633234293.png?format=webp&width=1186&height=250)
Climb Bio to Present at Upcoming Investor Conferences
ByAinvest
Monday, Aug 25, 2025 2:44 pm ET1min read
Climb Bio, a clinical-stage biotech company, will present at several investor conferences in September. The company's executive team will participate in fireside chats and one-on-one investor meetings at the Cantor Global Healthcare Conference, Baird Global Healthcare Conference, Morgan Stanley Annual Global Healthcare Conference, and Stifel Virtual Immunology and Inflammation Forum. Live webcasts and replays will be available on the Climb Bio website.
Climb Bio, Inc. (Nasdaq: CLYM), a clinical-stage biotechnology company focused on immune-mediated disease therapeutics, has announced its participation in four major investor conferences in September 2025. The company will present at the Cantor Global Healthcare Conference, Baird Global Healthcare Conference, Morgan Stanley Annual Global Healthcare Conference, and Stifel Virtual Immunology and Inflammation Forum.The Cantor Global Healthcare Conference, scheduled for September 5, 2025, in New York, NY, will feature a fireside chat and one-on-one investor meetings. The Baird Global Healthcare Conference, on September 9, 2025, also in New York, NY, will include a fireside chat and one-on-one meetings. The Morgan Stanley Annual Global Healthcare Conference, held on September 10, 2025, will consist of one-on-one meetings only. The Stifel Virtual Immunology and Inflammation Forum, also on September 10, 2025, will include a presentation and one-on-one investor meetings.
Live webcasts will be accessible via the “Investors and News” section of the Climb Bio website, with replays available for 30 days after each event. Climb Bio's executive team will participate in these events to discuss the company's pipeline, including budoprutug, an anti-CD19 monoclonal antibody, and CLYM116, an anti-APRIL monoclonal antibody.
Climb Bio's participation in these conferences highlights the company's commitment to engaging with investors and providing updates on its progress in developing therapeutics for immune-mediated diseases. The events provide an opportunity for investors to gain insights into the company's pipeline and its potential for growth in the immunology sector.
[1] https://www.stocktitan.net/news/CLYM/climb-bio-to-present-at-upcoming-september-2025-investor-he5rx80touud.html
[2] https://www.marketscreener.com/news/climb-bio-to-present-at-upcoming-september-2025-investor-conferences-ce7c50d8d98af32c
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet